164 related articles for article (PubMed ID: 25148295)
1. Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives.
Papachristos A; Pippa N; Ioannidis K; Sivolapenko G; Demetzos C
J Liposome Res; 2015; 25(2):166-73. PubMed ID: 25148295
[TBL] [Abstract][Full Text] [Related]
2. Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine.
Salehi B; Selamoglu Z; S Mileski K; Pezzani R; Redaelli M; Cho WC; Kobarfard F; Rajabi S; Martorell M; Kumar P; Martins N; Subhra Santra T; Sharifi-Rad J
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31771220
[TBL] [Abstract][Full Text] [Related]
3. Liposomal encapsulated anti-cancer drugs.
Hofheinz RD; Gnad-Vogt SU; Beyer U; Hochhaus A
Anticancer Drugs; 2005 Aug; 16(7):691-707. PubMed ID: 16027517
[TBL] [Abstract][Full Text] [Related]
4. Role of liposomal anthracyclines in breast cancer.
Lorusso V; Manzione L; Silvestris N
Ann Oncol; 2007 Jun; 18 Suppl 6():vi70-3. PubMed ID: 17591837
[TBL] [Abstract][Full Text] [Related]
5. Overview of novel strategies for the delivery of anthracyclines to cancer cells by liposomal and polymeric nanoformulations.
Alavi M; Varma RS
Int J Biol Macromol; 2020 Dec; 164():2197-2203. PubMed ID: 32763404
[TBL] [Abstract][Full Text] [Related]
6. [Nanostructured liposomal systems as transport agents for anticancer drugs].
Baryshnikov AIu
Vestn Ross Akad Med Nauk; 2012; (3):23-31. PubMed ID: 22712271
[TBL] [Abstract][Full Text] [Related]
7. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Theodoulou M; Hudis C
Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
[TBL] [Abstract][Full Text] [Related]
8. New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal locked-in dendrimers) for cancer therapy.
Gardikis K; Hatziantoniou S; Bucos M; Fessas D; Signorelli M; Felekis T; Zervou M; Screttas CG; Steele BR; Ionov M; Micha-Screttas M; Klajnert B; Bryszewska M; Demetzos C
J Pharm Sci; 2010 Aug; 99(8):3561-71. PubMed ID: 20564386
[TBL] [Abstract][Full Text] [Related]
9. Liposome-encapsulated anticancer drugs: still waiting for the magic bullet?
Fanciullino R; Ciccolini J
Curr Med Chem; 2009; 16(33):4361-71. PubMed ID: 19835568
[TBL] [Abstract][Full Text] [Related]
10. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
11. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
12. Liposomal nanomedicines in the treatment of prostate cancer.
Kroon J; Metselaar JM; Storm G; van der Pluijm G
Cancer Treat Rev; 2014 May; 40(4):578-84. PubMed ID: 24216226
[TBL] [Abstract][Full Text] [Related]
13. Liposomal anthracyclines for breast cancer.
Sparano JA; Winer EP
Semin Oncol; 2001 Aug; 28(4 Suppl 12):32-40. PubMed ID: 11552228
[TBL] [Abstract][Full Text] [Related]
14. Liposomal nanomedicine for breast cancer therapy.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
Nanomedicine (Lond); 2011 Aug; 6(6):1085-100. PubMed ID: 21955078
[TBL] [Abstract][Full Text] [Related]
15. Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases.
Oku N
Biol Pharm Bull; 2017; 40(2):119-127. PubMed ID: 28154249
[TBL] [Abstract][Full Text] [Related]
16. Current status of liposomal porphyrinoid photosensitizers.
Skupin-Mrugalska P; Piskorz J; Goslinski T; Mielcarek J; Konopka K; Düzgüneş N
Drug Discov Today; 2013 Aug; 18(15-16):776-84. PubMed ID: 23591149
[TBL] [Abstract][Full Text] [Related]
17. Functional liposomes in the cancer-targeted drug delivery.
Tila D; Ghasemi S; Yazdani-Arazi SN; Ghanbarzadeh S
J Biomater Appl; 2015 Jul; 30(1):3-16. PubMed ID: 25823898
[TBL] [Abstract][Full Text] [Related]
18. Tumor targeting using liposomal antineoplastic drugs.
Huwyler J; Drewe J; Krähenbuhl S
Int J Nanomedicine; 2008; 3(1):21-9. PubMed ID: 18488413
[TBL] [Abstract][Full Text] [Related]
19. Liposomal drug delivery.
Ranson M; Howell A; Cheeseman S; Margison J
Cancer Treat Rev; 1996 Sep; 22(5):365-79. PubMed ID: 9118122
[No Abstract] [Full Text] [Related]
20. Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.
Gilabert-Oriol R; Ryan GM; Leung AWY; Firmino NS; Bennewith KL; Bally MB
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
